[{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Myovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Exscientia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"DSP-0038","moa":"5-HT1A","graph1":"Neurology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma Co., Ltd"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"KSP-1007","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Veneno Technologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"National Institutes of Biomedical Innovation, Health and nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"DSP-0546LP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enzomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Poxel","highestDevelopmentStatusID":"14","companyTruncated":"Sumitomo Pharma \/ Poxel"}]

Find Clinical Drug Pipeline Developments & Deals by Sumitomo Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : TWYMEEG (imeglimin hydrochloride), enhances insulin action by inhibiting hepatic glucose output and improving insulin signalling in both liver and skeletal muscle, in type 2 diabetes patients.

                          Brand Name : Twymeeg

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 07, 2024

                          Lead Product(s) : Imeglimin Hydrochloride

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Poxel

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : DSP-5336, an Investigational menin and mixed-lineage leukemia inhibitor, is being evaluated in patients with relapsed or refractory acute myeloid leukemia with a KMT2A rearrangement.

                          Brand Name : DSP-5336

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 15, 2024

                          Lead Product(s) : Enzomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : fH1,DSP-0546LP

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : National Institutes of Biomedical Innovation, Health and nutrition

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : fH1/DSP-0546LP is a vaccine candidate, specifically activates TLR7, being investigated for influenza.

                          Brand Name : fH1

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 22, 2024

                          Lead Product(s) : fH1,DSP-0546LP

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : National Institutes of Biomedical Innovation, Health and nutrition

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.

                          Brand Name : Gemtesa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 13, 2024

                          Lead Product(s) : Vibegron

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.

                          Brand Name : SEP-363856

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 15, 2024

                          Lead Product(s) : Ulotaront

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : $30.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.

                          Brand Name : Orgovyx

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 12, 2024

                          Lead Product(s) : Relugolix

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

                          Brand Name : Orgovyx

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 24, 2023

                          Lead Product(s) : Relugolix

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

                          Brand Name : Orgovyx

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 23, 2023

                          Lead Product(s) : Relugolix

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Veneno will conduct a program to obtain functional peptides (DRPs) for ion channels targeted by Sumitomo Pharma using Veneno Technologies' next-generation peptide discovery technology, the PERISS™ method (intra-periplasm secretion ...

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          April 18, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Recipient : Veneno Technologies

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement includes the marketing alliance for JR-051 (agalsidase beta BS), a biosimilar of Fabrazyme, a therapeutic enzyme, being sold by JCR for the treatment of Fabry disease.

                          Brand Name : JR-051

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 01, 2022

                          Lead Product(s) : Agalsidase Beta

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : JCR Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank